Trial Profile
Immunogenicity and Safety of Recombinant Human Papillomavirus Bivalent(Type 16 and 18) Vaccine (Yeast) in Healthy Females
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Shanghai Zerun Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors Shanghai Zerun Biotechnology Co
- 12 Apr 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2016 New trial record